BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26604804)

  • 1. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review.
    Patterson MF; Borish L; Kennedy JL
    J Asthma Allergy; 2015; 8():125-34. PubMed ID: 26604804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the risk of infection events in patients with asthma receiving
    Giossi R; Pani A; Schroeder J; Scaglione F
    Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
    Giannetti MP; Cardet JC
    Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benralizumab for the treatment of asthma.
    Saco TV; Pepper AN; Lockey RF
    Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
    Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
    N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
    Edris A; De Feyter S; Maes T; Joos G; Lahousse L
    Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
    Corren J
    Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
    J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophils Target Therapy for Severe Asthma: Critical Points.
    Brussino L; Heffler E; Bucca C; Nicola S; Rolla G
    Biomed Res Int; 2018; 2018():7582057. PubMed ID: 30498762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
    Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
    Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
    Roufosse F
    Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.